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Parc: A Cytoplasmic Anchor for p53
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key events in the p53-mediated stress response, subcel-College of Physicians and Surgeons
lular localization also appears to play a critical role inColumbia University
the regulation of p53 function (Vousden, 2002; Jimenez1150 St. Nicholas Avenue
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inactivated by abnormal cytoplasmic sequestration in
many tumor types including inflammatory breast carci-
noma, undifferentiated neuroblastoma, colorectal carci-Summary
noma, and retinoblastoma; constitutive cytoplasmic lo-
calization of p53 in these tumors has been linked withNuclear localization of p53 is essential for its tumor
poor response to chemotherapy, tumor metastasis, andsuppressor function. Here, we have identified Parc, a
poor long-term patient survival (Moll et al., 1992, 1996;Parkin-like ubiquitin ligase, as a cytoplasmic anchor
Bosari et al., 1995; Sun et al., 1992; Schlamp et al., 1997;protein in p53-associated protein complexes. Parc di-
Ueda et al., 1995).rectly interacts and forms a1 MDa complex with p53
The p53 protein contains three lysine-rich nuclear lo-in the cytoplasm of unstressed cells. In the absence
calization signals (NLSs) in the C terminus (Liang et al.,of stress, inactivation of Parc induces nuclear localiza-
1998; Shaulsky et al., 1990). NLS I (aa 305–322) has beention of endogenous p53 and activates p53-dependent
implicated as the primary NLS, and NLS II (aa 369–375)apoptosis. Overexpression of Parc promotes cyto-
and NLS III (aa 379–384) appear to increase the effi-plasmic sequestration of ectopic p53. Furthermore,
ciency of nuclear import mediated by NLS I (Shaulsky etabnormal cytoplasmic localization of p53 was ob-
al., 1990). Many NLS-containing transcriptional factors,served in a number of neuroblastoma cell lines; RNAi-
such as c-Myc, Max, and c-Fos, are exclusively presentmediated reduction of endogenous Parc significantly
in nuclei. However, since subcellular localization of thesensitizes these neuroblastoma cells in the DNA dam-
p53 protein is a dynamic process and the levels of p53age response. These results reveal that Parc is a criti-
distributed in the cytoplasm and nucleus vary with differ-cal regulator in controlling p53 subcellular localization
ent cell types and cellular conditions (Jimenez et al.,and subsequent function.
1999), cellular factors/pathways that specifically regu-
late both nuclear import and export of p53 are likely toIntroduction
exist.
A number of studies have shown that nuclear export ofThe p53 protein acting as a bona fide tumor suppressor
p53 is specifically regulated by Mdm2 (Tao and Levine,can induce cell growth arrest, apoptosis, and aging/
1999; Geyer et al., 2000; Boyd et al., 2000). p53 contains
cell senescence in response to various types of stress
a leucine-rich, rev-like nuclear export signal (NES) at the
(Vogelstein et al., 2000; Sharpless and DePinho, 2002).
C terminus (Stommel et al., 1999; Freedman and Levine,
p53 mutations have been well documented in more than 1998; Middeler et al., 1997), and recently, a second NES
half of all human tumors (Hollstein et al., 1999), and in in the p53 transactivation domain has also been identi-
the cells that retain wild-type p53, other defects in the fied (Zhang and Xiong, 2001). Mdm2 can significantly
p53 pathway also play an important role in tumorigen- enhance nuclear export of p53 through the C-terminal
eisis. p53 promotes tumor suppression through its abil- NES (Lohrum et al., 2001; Gu et al., 2001). In addition
ity to bind specific DNA sequences and function as a to its p53 binding domain, the ubiquitin ligase activity
transcription factor (El-Deiry et al., 1992). The impor- of Mdm2 is also critical for its ability to promote nuclear
tance of p53-mediated transcriptional activation is export of p53 (Geyer et al., 2000; Boyd et al., 2000).
underscored by the fact that the vast majority of tumor- Notably, the C-terminal lysine residues of p53 that serve
associated p53 mutations occur within the domain re- as both acetylation sites (Li et al., 2002b) and the sites
sponsible for sequence-specific DNA binding (Hollstein of Mdm2-mediated ubiquitination are also required for
et al., 1999). the enhancement of p53 nuclear export by Mdm2 (Loh-
Tight regulation of p53 is essential for maintaining rum et al., 2001; Gu et al., 2001).
normal cell growth and for its effect on tumorigenesis. The mechanism by which p53 is diffusely distributed
Wild-type p53 is a short-lived protein that is maintained in normal unstressed cells remains unknown. Since the
as a latent form in unstressed cells. The precise mecha- Mdm2 protein is often undetectable in unstressed cells,
cellular factors other than Mdm2 are likely involved in
retaining the p53 protein in the cytoplasm under these*Correspondence: wg8@columbia.edu
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conditions. A number of proteins have been proposed
to serve as cytoplasmic anchor proteins to block nuclear
localization of p53, including ribosomal proteins (Fon-
toura et al., 1997; Abou Elela and Nazar, 1997), Hsc70
(Gannon and Lane, 1991), vimentin (Klotzsche et al.,
1998), tubulin (Giannakakou et al., 2000), and F-actin
(Metcalfe et al., 1999). As each of these identified pro-
teins is highly abundant and the specificity of their inter-
actions with p53 needs further verification, none of them
has received wide acceptation as the bona fide cyto-
plasmic anchor of p53. Nevertheless, these studies indi-
cate that a fraction of p53 resides in the cytoplasm and
the levels of cytoplasmic p53 proteins may be regulated
by cytoplasmic factors.
To reevaluate the hypothesis that certain cytoplasmic
factors may directly affect the subcellular localization
of p53, we have biochemically purified p53-containing
protein complexes from the cytoplasm of unstressed
cells and identified a protein, Parc (p53-associated, Par-
kin-like cytoplasmic protein), as a key component of
these complexes. This discovery reveals an important
regulatory pathway that controls the subcellular local-
ization of p53 and its subsequent biological function.
Results
Affinity Purification of p53-Containing Protein
Complexes from the Cytoplasm
of Unstressed Human Cells
To identify the key cytoplasmic binding partner for p53,
we used an epitope-tagging strategy to isolate p53- Figure 1. Identification of p270/Parc as a Cytoplasmic p53-Inter-
containing protein complexes from cells. Similar ap- acting Protein
proaches have been used successfully in our lab and (A) Schematic representation of the Flag-p53(175) protein used for
others to purify bona fide protein complexes such as affinity purification of p53-interacting proteins. The arginine residue
of the DNA binding domain is replaced with histidine (aa 175).the SMCC/TRAP and HDAC1 complexes (Gu et al., 1999;
(B) Collodial-blue staining of the protein marker (lane 1), a controlLuo et al., 2000). However, since expression of wild-
eluate from M2 beads loaded with parental H1299 cytoplasmic celltype p53 strongly induces apoptosis in human cells, it
extract (lane 2), and affinity-purified Flag-p53(175) complexes from
is very difficult to obtain a sufficient quantity of cell a cytoplasmic extract of the Flag-p53(175)/H1299 stable cell line
extract for further protein purification. Also, a predomi- (lane 3). Specific p53-interacting protein bands were peptide se-
nantly nuclear pattern of p53 localization is usually ob- quenced by mass spectrometry, and the p270/Parc peptide se-
tained when wild-type p53 is ectopically expressed in quences are presented.
(C) p270/Parc is present in cytoplasmic, but not nuclear, p53-con-human cells (Geyer et al., 2000; Boyd et al., 2000; also
taining complexes. Western blot analysis of M2 immunoprecipitatessee Figure 6). Taking these factors into consideration,
from parental H1299 cytoplasmic extract (lane 1), Flag-p53(175)/we generated a derivative of the human lung carcinoma
H1299 cytoplasmic (lane 2), and nuclear (lane 3) extracts by immu-
p53 null H1299 cell line that stably expresses a tumor- noblotting with p270/Parc-specific antibody (upper) or p53-specific
derived human p53 mutant [p53(175)] containing an DO-1 antibody (lower).
N-terminal FLAG epitope (Flag-p53[175]) (Figure 1A). Im- (D) p270/Parc mRNA is ubiquitously expressed. A multiple tissue
Northern filter was hybridized with p270/Parc (upper) or actin (lower)portantly, a significant proportion of the ectopic p53
cDNA probes.protein was present in the cytoplasm of this stably trans-
fected cell line (data not shown; also see Figures 1B
and 1C). Cloning and Initial Characterization of Parc
To isolate protein complexes containing epitope- (p53-Associated, Parkin-Like
tagged p53, cytoplasmic extracts from Flag-p53(175)- Cytoplasmic Protein)
expressing H1299 cells and from control cells (parental A full-length human p270 cDNA was assembled by exon
H1299) were subjected to affinity chromatography on prediction from genomic sequences, RACE (rapid ampli-
M2 (Flag antibody) agarose. As shown in Figure 1B, a fication of cDNA ends), and homology alignment with
major protein band of 270 kDa specifically copurified the partial sequence of KIAA0708. The full-length cDNA
with cytoplasmic p53 from Flag-p53(175)-expressing encodes a 2517 amino acid protein (about 800 amino
H1299 cells (lane 3), but not from parental H1299 cells acids longer than the KIAA0708 sequences, Figure 2B).
(lane 2). Peptide sequencing of this band by mass spec- Northern blot analysis showed that the p270 mRNA is
trometry revealed three peptide sequences, all of which highly expressed in testis but very low in thymus (Figure
matched a single, partial cDNA clone (GeneBank acces- 1D). Nevertheless, it is ubiquitously expressed in all dif-
ferent tissues.sion number Gi4558043, also known as KIAA0708).
Regulation of p53 Subcellular Localization by Parc
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Figure 2. Parc Contains the Ring-IBR-Ring Motif and a C-Terminal Cullin Homology Domain (CCH)
(A) Schematic representation of the Parc and Parkin polypepetides.
(B) The amino acid sequence of Parc, with the CCH, RING, and IBR domains highlighted in colors.
(C) An alignment of the CCH domain of Parc with those of human cullin1 (hCul1) and cullin2 (hCul2), C. elegans cullin1 (cCul1) and cullin2
(cCul2), and yeast cullinA (yCulA). Homologous amino acid residues are highlighted in colors.
(D) An alignment of the IBR domain of Parc with those of Parkin, human ariadne (hAriadne) and ariadne2 (hAriadne2), and D. melanogaster
ariadne (dAriadne) and ariadne2 (dAriadne2). Homologous amino acid residues are highlighted in colors.
(E) An alignment of the RING domains of Parc (RING1, RING2) with those of Parkin (hParkinR1, hParkinR2), human Ariadne (hAriadne), human
BRCA1 (hBRCA1), and human PML (hPML1) proteins. Homologous amino acid residues are highlighted in colors.
Remarkably, the C-terminal sequences of p270 pos- Ring-IBR-Ring is responsible for the intrinsic ubiquitin
ligase activity of Parkin (Shimura et al., 2000). Parkinsess a signature motif, the Ring-IBR-Ring domain, that
was first identified in the C terminus of Parkin (Figures also contains an ubiquitin-homology domain at the N
terminus that is absent from Parc. Interestingly however,2A, 2D, and 2E), the protein implicated in an autosomal
recessive form of Parkinson’s disease (PD) (Kitada et al., Parc has a unique motif that is highly homologous to
the C terminus of the Cullin proteins (here designated1998; Shimura et al., 2000). Accordingly, we designated
p270 as the p53-associated, Parkin-like cytoplasmic as the C-terminal Cullin Homology [CCH] domain) (Fig-
ure 2C). The Cullins, including Cul1 and Cul2, are criticalprotein Parc. Biochemical studies have shown that the
Cell
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Figure 3. The Interaction between p53 and
Parc In Vitro and In Vivo
(A) Direct interactions of Parc with GST-p53.
The wild-type GST-p53 full-length protein
(GST-p53) (lane 4), the mutant GST-p53 full-
length protein (GST-p53[175]) (lane 3), the N
terminus of p53 protein (1-73) (lane 7), the
middle part of p53 (100-290) (lane 8), the C
terminus of p53 (290-393) (lane 9), or GST
alone (lanes 2 and 5) were used in a GST
pull-down assay with in vitro translated 35S-
labeled full-length Parc.
(B) The N terminus of Parc directly interacts
with GST-p53. The GST-p53 full-length pro-
tein (GST-p53) (lanes 3, 6, and 9) or GST alone
(lanes 2, 5, and 8) were used in a pull-down
assay with the in vitro translated 35S-labeled
N terminus of Parc (1–770) (lanes 1–3), the
middle part of Parc (770–1460) (lanes 4–6),
and the C terminus of Parc (1460–2517) (lanes
7–9).
(C) Coimmunoprecipitation of p53 with Parc
from U2OS cells. Western blot analysis of in-
dicated whole-cell extract (WCE) (lane 1) and
immunoprecipitates with a Parc-specific anti-
body (lane 3) or preimmune serum (lane 2) by
anti-p53 monoclonal antibody DO-1 (lower)
or anti-Parc antibody (top).
(D) Coimmunoprecipitation of Parc with p53
from U2OS cells. Western blot analysis of
whole-cell extract (WCE) (lane 1) or immuno-
precipitates with anti-p53 monoclonal anti-
body DO-1 (lane 3) or control immunoprecipi-
tates with anti-Ras antibody (lane 2) by a
Parc-specific antibody.
(E) Endogenous p53 was codepleted with
endogenous Parc from U2OS cytoplasmic
extracts by anti-Parc antibody. U2OS cyto-
plasmic extracts were incubated with preim-
mune serum or -Parc antibody in the pres-
ence of protein A/G beads. Preimmune and
-Parc immunoprecipitation flowthroughs
(lanes 2 and 3) and U2OS cytoplasmic extract (lane 1) were resolved in 8% SDS PAGE and immunoblotted with anti-Parc (upper) or anti-p53
monoclonal antibody DO-1 (middle) or actin antibody (AC-15, bottom).
(F) Endogenous Parc is found in cytoplasmic, but not nuclear, extracts of U2OS cells. Western blot analysis of cytoplasmic (lane 1) and nuclear
(lane 2) extracts from U2OS cells with Parc-specific (upper) or p53-specific (DO-1) antibodies.
(G) Parc forms a 1 Mda complex with p53 in the cytoplasm of U2OS cells. Chromatographic fractions (lanes 2–11) generated by the gel
filtration (Superose 6, SMART system) of Flag-Parc-containing complexes (lane 1) from the cytoplasmic extract of Flag-Parc/U2OS stable
cells were immunoblotted with anti-Parc (upper) and anti-p53 (DO-1) (lower) antibodies.
components of several ubiquitin ligase complexes, such indicate that the N terminus of Parc interacts with the
C terminus of p53.as the anaphase-promoting complex (APC/C) and the
Skp-Cullin-F box complex (SCF) (Pickart, 2001). To confirm the interaction between p53 and Parc in
vivo, we developed an affinity-purified polyclonal antise-
rum against the C-terminal 100 residues of Parc (aminoParc Interacts with p53 Both In Vitro and In Vivo
To confirm the physical interaction between p53 and acids 2417–2517), a region that shows no apparent ho-
mology with any known protein (Figure 2A). Upon West-Parc, we first tested whether Parc binds to p53 in vitro.
As shown in Figure 3A, 35S-labeled in-vitro-translated ern blot analysis, this antibody specifically detects Parc
proteins in human cell extracts (lane 1, Figure 3C). Next,Parc bound to immobilized GST-p53 (wild-type) and the
p53 mutant form GST-p53(175) (lanes 3 and 4), but not we used this antibody to investigate whether the endog-
enous Parc and p53 polypeptides interact in vivo. Cellto GST alone (lane 2); Parc bound the C terminus of
p53 (GST-p53CT) (lane 9) but showed no binding to the extracts from human U2OS cells, which express wild-
type p53, were immunopreciptated with -Parc or withN-terminal domain of p53 (GST-p53NT) (lane 7). A similar
strategy was used to map the p53-interacting se- the corresponding preimmune serum. As expected,
Western analysis revealed that this antibody immuno-quences of Parc. As shown in Figure 3B, p53 was associ-
ated with the N terminus of Parc. Neither the central precipitated endogenous Parc (lane 3, top, Figure 3C).
More importantly, p53 was clearly detected in the immu-region nor C-terminal region that encompasses the CCH
domain and Ring-IBR-Ring motif showed strong binding noprecipitations obtained with the -Parc antiserum
(lane 3), but not the preimmune serum (lane 2, bottom,with p53 (lane 3 versus lanes 6 and 9). Thus, our data
Regulation of p53 Subcellular Localization by Parc
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Figure 3C). Conversely, endogenous Parc was readily Parc occurred in the presence of E1, E2 (UBCH7), and
ubiquitin (lane 2). Furthermore, highly ubiquitinated spe-immunoprecipated with the p53-specific monoclonal
antibody DO-1 (lane 3, Figure 3D), but not with a control cies of Parc were readily detected in human cells that
coexpressed Flag-tagged Parc and HA-tagged ubiquitinantibody (anti-Ras monoclonal antibody) (lane 2, Figure
3D). Similar results were also obtained in other cell lines, (lane 3, Figure 4C).
To explore the functional relationship between p53such as human lung carcinoma H460 cells (see Supple-
mental Figure S1 online at http://www.cell.com/cgi/ and Parc, we tested whether Parc directly induces p53
ubiquitination. As indicated in Figure 4D, a high level ofcontent/full/112/1/29/DC1). Taken together, these data
indicate that p53 and Parc interact both in vitro and in ubiquitinated p53 was found in cells cotransfected with
Mdm2 (lane 2) (Li et al., 2002a); however, Parc expres-vivo.
sion failed to induce significant ubiquitination of p53
(lane 3 versus lane 2). Likewise, using an in vitro assay,Parc Forms a 1 MD Complex with p53
we detected strong ubiquitination of p53 by Mdm2, butin the Cytoplasm
not by Parc (lane 3 versus lane 2, Figure 4E). Moreover,Initial purification and identification of Parc showed that
while Mdm2 expression strongly induced p53 degrada-Parc is associated with p53 in cytoplasmic complexes
tion, Parc had no effect on the steady-state levels of p53(Figure 1B). To demonstrate that Parc is a cytoplasmic-
(Figure 4F). Notably, we also failed to detect a significantspecific p53 binding protein, we tested whether p53 is
effect of Parc on the cellular levels of p53mNLS (Figurepresent exclusively in p53-associated cytoplasmic com-
4G), an NLS mutant of p53 that, like Parc, resides exclu-plexes by Western analysis with anti-Parc antibody. As
sively in the cytoplasm (data not shown). Thus, Parc isindicated in Figure 1C, Parc is completely undetectable
a potential ubiquitin ligase but fails to directly inducein p53-associated complexes obtained from nuclear ex-
p53 degradation.tracts of the Flag-p53(175) stable cell line (top, lane 3
versus lane 2), although similar levels of p53 were readily
immunopreciptitated from both the cytoplasmic and nu- RNAi Ablation of Parc Induces Nuclear Localization
clear fractions of these cells (bottom). Moreover, West- of p53 and p53-Dependent Apoptosis
ern analysis of cellular fractions from native U2OS cells Since we did not observe a significant effect of Parc on
showed that the endogenous Parc protein is present p53 ubiquitination, it is likely that Parc may regulate
only in cytoplasmic, but not nuclear, extracts (top, Figure p53-mediated function through other mechanisms. To
3F). In accord with these findings, we also observed a elucidate the physiological significance of the Parc-p53
predominantly cytoplasmic pattern of immunofluores- interaction, we examined the functional consequences
cent staining in human lung carcinoma H1299 cells tran- of RNAi ablation of endogenous Parc. For this purpose,
siently transfected with a Flag-tagged Parc polypeptide U2OS cells, which express both Parc and wild-type p53
(Figure 4A). proteins (Figure 3F), were transfected with either a Parc-
Strikingly, through immunodepletion of the Parc pro- specific RNA oligonucleotide (Parc-RNAi) or a control
tein from cytoplasmic extracts, we found that more than oligonucleotide (control-RNAi). As shown in Figure 5A,
70% of cytoplasmic p53 was also codepleted from the endogenous Parc polypeptides were nearly undetect-
extract, indicating that the majority of cytoplasmic p53 able after three consecutive oligofectamine-mediated
is associated with endogenous Parc (lane 3 versus lanes transfections (top, lane 2 versus lane 1), while the level
1 and 2, Figure 3E). To further evaluate whether Parc of control protein (actin) remained the same (bottom).
can form a cytoplasmic complex with endogenous p53 Strikingly, ablation of Parc expression strongly induced
in unstressed cells, we stably transformed U2OS cells the expression of p21, one of the key transcriptional
with Flag-tagged Parc. To isolate Parc-containing com- targets of p53, despite the fact that the steady-state
plexes, the cytoplasmic extract was subjected to affinity levels of p53 were unchanged (middle, lane 2 versus
chromatography for the Parc-containing complexes. As lane 1, Figure 5A).
expected, Western analysis showed that p53 is present Next, we examined the effect of Parc on p53-mediated
in the Parc-containing complexes (lane 1, Figure 3G). apoptosis. As shown in Figure 5C, Parc-RNAi treated
Moreover, when these complexes were subjected to cells were susceptible to programmed cell death, with
gel-filtration chromatography on Superose 6 (SMART about 49.3% of the cells apoptotic (II) while the control
system) as described previously (Gu et al., 1999), p53 transfected U2OS cells (control-RNAi) showed no signif-
and Parc coeluted in fractions 8–16 with an apparent icant apoptosis under the same conditions (I). Similar
size of 1 MDa (Figure 3G). Since coelution of purified results were also obtained with the TUNEL assay (data
protein complexes on gel-filtration chromatography re- not shown). Furthermore, the same experiments were
quires a very stable interaction, our data demonstrate also performed in the human p53 null cell line H1299.
that Parc strongly interacts with p53 in the cytoplasm As shown in Figure 5A, although endogenous Parc ex-
of unstressed human cells. pression was successfully abrogated by RNAi, neither
p21 activation nor significant apoptosis was detected
in these cells (lanes 3 and 4, Figure 5A; III and IV, FigureParc Has an Ubiquitin Ligase Activity but Fails
to Directly Induce p53 Degradation 5C). These results indicate that ablation of endogenous
Parc expression significantly induces p53-mediatedLike Parkin, Parc contains the Ring-IBR-Ring motif (Fig-
ure 2A). Since this motif is required for Parkin-mediated transcriptional activation and activates p53-dependent
apoposis.ubiquitination (Shimura et al., 2000), we asked whether
Parc also contains an intrinsic ubiquitin ligase activity. To explore the molecular mechanism by which Parc
affects p53 function, we tested whether Parc directlyAs indicated in Figure 4B, in vitro self-ubiquitination of
Cell
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Figure 4. Parc Is a Cytoplasmic Ubiquitin Ligase
(A) Ectopically expressed Parc is diffusely localized in the cytoplasm of Flag-Parc-transfected H1299 cells. These cells were stained with anti-
Flag monoclonal antibody to detect Parc.
(B) Self-ubiquitination of Parc in vitro. In vitro translated 35S labeled Parc was incubated with E1, E2 (GST-UbcH7), and His-ubiquitin.
(C) Ubiquitination of Parc in vivo. Immunoprecipitations from H1299 cells transfected with HA-Ub (lane 1), Flag-Parc (lane 2), or both (lane 3)
by the M2 (Flag) antibody, were immunoblotted with anti-HA monoclonal antibody.
(D) Parc does not ubiquitinate p53 effectively in vivo. M2 immunoprecipitations from H1299 cells cotransfected with Flag-ubiquitin and either
p53 alone (lane 1), or p53 and mdm2 (lane 2), or with p53 and Parc (lane 3) were immunoblotted with anti-p53 monoclonal antibody (DO-1).
(E) Parc does not ubiquitinate p53 effectively in vitro. In vitro ubiquitination reactions containing GST-p53 incubated either alone (lane 1), with
GST-mdm2/GST-UbcH5 (lane 2), or Flag-Parc/GST-UbcH7 (lane 3) were immunoblotted with anti-p53 monoclonal antibody (DO-1). Mammalian
E1 was included in all three reactions (lanes 1–3).
(F) Parc does not promote degradation of wild-type p53. H1299 cell extracts transfected with CMV-p53/CMV-GFP (lane 1), or CMV-53/CMV-
GFP and CMV-mdm2 (lane 2), or CMV-p53/CMV-GFP and CMV-Parc (lane 3) were immunoblotted with anti-p53 antibody (DO-1) (upper) or
anti-GFP monoclonal antibody (lower).
(G) Parc does not promote degradation of the p53-mNLS mutant (K319A, K320A, K321A). H1299 transfections and immunoblotting were done
as described in (F).
Regulation of p53 Subcellular Localization by Parc
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Figure 5. RNAi Ablation of Endogenous Parc
Induces Nuclear Localization of p53 and p53-
Dependent Apoptosis
(A) RNAi ablation of endogenous Parc ex-
pression in U2OS and H1299 cells. Whole-
cell extracts from Parc-RNAi or control-RNAi
treated cells (U2OS and H1299), were immu-
noblotted with anti-Parc, anti-p53 (DO-1),
anti-p21 (C19) and anti-actin (AC-15) anti-
bodies.
(B) Quantitation of subcellular p53 localiza-
tion in U2OS cells transfected with Parc-RNAi
or control oligonucleotide. The data repre-
sent the average of three experiments with
standard deviations indicated.
(C) p53-dependent induction of apoptotic re-
sponse by Parc RNAi ablation. U2OS and
H1299 cells transfected with either Parc-RNAi
and control oligonucleotides were analyzed
for apoptotic cells (sub-G1) according to DNA
content (PI staining).
(D) Subcellular localization of p53 in U2OS
cells transfected with Parc-RNAi or control
oligonucleotides. The transfected cells were
immunostained with anti-p53 antibody (1801)
(visualized by green fluorescence) and coun-
terstained with DAPI to visualize the nuclei.
controls subcellular localization of p53. Under normal al., 2000). However, overexpression of full-length Parc
strongly induced cytoplasmic retention of p53, withconditions, p53 is diffusely distributed in the cytoplasm
of U2OS cells, as shown by immunofluorescence stain- more than 87% of cells showing cytoplasmic p53 local-
ization (bottom, Figures 6A and 6C). In contrast, Parcing with a p53-specific monoclonal antibody (1801) (top,
Figure 5D). Strikingly however, after RNAi ablation of had no effect on another nuclear protein, c-Myc (Figure
6B), indicating that Parc-mediated cytoplasmic seques-endogenous Parc, p53 was predominantly relocalized
to the nucleus of these cells (bottom, Figure 5D); the tration is specific for p53.
To identify the sequences of Parc that are responsibleexclusive nuclear staining of p53 was found in as many
as 80% of total Parc-RNAi-treated cells compared with for cytoplasmic retention of p53, the same assay was
used to evaluate selected segments of the Parc poly-only 12% of control cells (Figure 5B). Similar results
were also obtained in the cells expressing mutated p53 peptide. As summarized in Figure 6C, the subcellular
localization of p53 was not altered by overexpressionproteins (see Supplemental Figure S2 online at http://
www.cell.com/cgi/content/full/112/1/29/DC1). These of individual Parc segments corresponding to either the
CCH domain (residues 1695–1953), the Ring-IBR-Ringresults indicate that RNAi ablation of Parc expression
activates p53-mediated function by regulating its sub- motif (residues 2070–2282), or two N-terminal regions
(residues 1–770 or 770–1600). In contrast, however, acellular localization.
segment encompassing both the N-terminal sequences
and the CCH domain (residues 1–1960) readily inducedOverexpression of Parc Induces Cytoplasmic
cytoplasmic relocalization of p53. These data also indi-Sequestration of p53
cate that the Ring-IBR-Ring motif is not required forTo elucidate the mechanism by which Parc affects sub-
Parc-mediated sequestration of p53.cellular localization of p53, we investigated whether
Parc overexpression directly promotes cytoplasmic re-
tention of p53. As indicated in Figure 6A, ectopic expres- Reduction of Endogenous Parc in Neuroblastoma
Cells Also Induces p53 Nuclear Localizationsion of wild-type p53 yields predominantly nuclear stain-
ing (top), with less than 10% of cells showing clear Many neuroblastoma cell lines display predominantly
cytoplasmic localization of wild-type p53 (Moll et al.,cytoplasmic localization (Geyer et al., 2000; Boyd et
Cell
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Figure 6. Overexpression of Parc Promotes
Cytoplasmic Sequestration of Ectopic p53
(A) Subcellular localization of ectopic p53 in
H1299 cells transfected with CMV-p53 alone or
with CMV-p53 and CMV-Parc. The transfected
cells were immunostained with anti-p53 anti-
body (visualized by green fluorescence) and
counterstained with DAPI to visualize the
nuclei.
(B) Subcellular localization of ectopic Myc in
H1299 cells transfected with CMV-Flag-Myc
alone or CMV-Flag-Myc and CMV-Parc. The
transfected cells were immunostained with
anti-Flag monoclonal antibody (M2) (visual-
ized by red fluorescence) and counterstained
with DAPI to visualize the nuclei.
(C) The Ring-IBR-Ring domain of Parc is not
required for Parc-mediated cytoplasmic se-
questration of ectopic p53. H1299 cells were
transfected with CMV-p53 alone, with CMV-
p53 and CMV-Parc (full-length), or with CMV-
p53 and various CMV-Parc deletion constructs.
The transfected cells were immunostained as
described in (A) and the p53-positive cells
were quantitated for subcellular p53 local-
ization.
1996; Sengupta et al., 2000; Stommel et al., 1999; Zaika ing pattern in about 35% of cells, compared to less than
10% in the control cells (Figures 7C and 7E). Further-et al., 1999). The mechanisms by which p53 is seques-
tered in the cytoplasm of these cells are not completely more, expression of p21, a major transcriptional target
of p53, was significantly induced despite the fact thatunderstood. Interestingly, as indicated in Figures 7A and
7B, the Parc protein is highly expressed in the neuro- the total level of p53 polypeptides was unchanged by
Parc-specific RNAi treatment (middle, Figure 7D).blastoma cell lines that we tested, including IMR32,
KCNR, SK-N-AS, and LAN5, compared to either normal
human brain tissues or human glioma cell lines. RNAi-Mediated Parc Reduction Restores a Strong
p53-Dependent Stress ResponseTo explore the role of Parc in this phenomenon, we
tested whether inactivation of endogenous Parc expres- in Neuroblastoma Cells
Neuroblastoma cells and other types of tumor cells thatsion by RNAi modulates the subcellular localization of
p53 in the SK-N-AS and IMR32 neuroblastoma lines. As show constitutive cytoplasmic localization of p53 often
exhibit an impaired response to low levels of DNA dam-indicated in Figure 7D, the protein levels of endogenous
Parc in these cells were significantly decreased by Parc- age treatment (Moll et al., 1996). Therefore, we tested
whether a normal DNA damage response could be re-RNAi treatment (top), although the reduction was less
than that obtained by the same technique in U2OS cells stored in neuroblastoma cells by RNAi-mediated inhibi-
tion of Parc function. As indicated in Figure 8, native(Figure 5A). This presumably reflects the higher steady-
state levels of endogenous Parc and lower transfection SK-N-AS neuroblastoma cells responded poorly to
treatment with low levels of the genotoxic drug etopo-efficiency of neuroblastoma cells. Nevertheless, RNAi-
mediated reduction of endogenous Parc also leads to side; only 20% of cells showed nuclear localization of
p53 (II, Figure 8A) and less than 15% became apoptoticnuclear localization of p53 in both SK-N-AS and IMR32
cells; the typical punctuated pattern of cytoplasmic p53 (II, Figure 8B). However, after treatment with Parc-RNAi,
almost 70% of the cells showed nuclear staining of p53staining was converted to a predominantly nuclear stain-
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Figure 7. RNAi-Mediated Reduction of Parc
Induces p21 Activation and p53 Nuclear Lo-
calization in Neuroblastoma Cells
(A) Parc is highly expressed in neuroblastoma
cell lines. Whole-cell extracts of primary fi-
broblast (IMR90) (lane 1) and neuroblastoma
cell lines (IMR32, KCNR, SK-N-AS, LAN-5)
(lanes 2–5) were immunoblotted with anti-
Parc antibody (upper) and anti-actin antibody
(lower).
(B) Parc expression levels in human cerebral
cortex, glioma, and neuroblastoma cell lines.
Western blot analysis of whole-cell extracts
of human cerebral cortex from two healthy
individuals (# 85, #93) (lanes 1 and 2), SNB19
and SF188 human glioma cell lines (lanes 3
and 4), and neuroblastoma cell line (IMR32)
(lane 5) with anti-Parc antibody (upper) and
anti-actin antibody (lower).
(C) Subcellular localization of p53 in neuro-
blastoma cells (SK-N-AS) transfected with
Parc-RNAi or control oligonucleotide. The
transfected cells were immunostained with
anti-p53 antibody (1801) (visualized by green
fluorescence) and counterstained with DAPI
to visualize the nuclei.
(D) RNAi-mediated reduction of Parc in SK-
N-AS and IMR32 neuroblastoma cell lines.
Whole-cell extracts from Parc-RNAi or con-
trol oligonucleotide transfected cells, were
immunoblotted with anti-Parc, anti-p53
(DO-1), anti-p21 (C19), and anti-actin (AC-15)
antibodies.
(E) Quantization of subcellular p53 localiza-
tion (cytoplasmic and nuclear) in SK-N-AS
and IMR32 neuroblastoma cells transfected
with Parc-RNAi or control oligonucleotide.
The data represent the average of three ex-
periments with standard deviations indi-
cated.
(III, Figure 8A) and more than half (56.4%) became apo- activation through inducing p53 nuclear localization.
Furthermore, our results also indicate that the levels ofptotic with the same dose of etoposide (V versus II,
Figure 8B), whereas Parc-RNAi treatment alone only Parc proteins are relatively high in neuroblastoma cells.
It is conceivable, therefore, that the high levels of Parcinduced apoptosis in 17.1% of cells (IV, Figure 8B). Thus,
the combination of RNAi-mediated Parc reduction and in these cells may prevent nuclear translocation of p53,
even in the presence of genotoxic stress although otherDNA damage restores a strong p53-mediated apoptotic
response in neuroblastoma cells. mechanisms may also contribute to this phenomenon
(Stommel et al., 1999). In consistence with this notion,
we have also shown that RNAi-mediated reduction ofDiscussion
Parc protein levels can restore a strong p53-dependent
stress response in these neuroblastoma cells. As such,The present data reveal the existence of a key cyto-
the Parc-mediated pathway of p53 regulation may proveplasmic protein Parc (p53-associated, Parkin-like cyto-
to be a potential target for cancer therapy. In particular,plasmic protein) that is critically involved in the regula-
agents that down-regulate Parc protein levels or abro-tion of p53 subcellular localization and subsequent
gate the Parc-p53 interaction may sensitize tumor cellsfunction. As a transcription factor, nuclear localization
to p53-dependent apoptosis.of p53 is essential for its role in tumor suppression (Vous-
den, 2002; Jimenez et al., 1999). However, p53 is dif-
fusely distributed in the cytoplasm of normal unstressed Parc Plays a Critical Role in the Regulation
of Subcellular Localization of p53cells; many types of tumors cells, including neuro-
blastoma cells, have abnormal cytoplasmic localization In unstressed cells, p53 is diffusely distributed, and p53-
mediated function appears to be severely inhibited.of p53 and an impaired p53-dependent stress response
despite the fact that they express wild-type p53 proteins While no obvious effect on the total p53 protein levels
by RNAi-mediated ablation of endogenous Parc, the p53(reviewed in Jimenez et al., 1999; Moll et al., 1992, 1995,
1996). We show that the majority of cytoplasmic p53 is polypeptides are relocated to the nucleus, and p53-
mediated functions are also strongly activated in thetightly associated with endogenous Parc. In the absence
of stress, inactivation of endogenous Parc leads p53 absence of stress. Conversely, overexpression of Parc
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Figure 8. The Combination of Parc Reduc-
tion and Genotoxic Stress Strongly Activates
p53-Mediated Apoptosis in Neuroblastoma
Cells
(A) Subcellular localization of p53 in neuro-
blastoma cells (SK-N-AS) transfected with
Parc-RNAi or control-RNAi and treated with
0.25 M etoposide.
(B) Enhancement of the DNA damage-
induced apoptotic response in neuro-
blastoma cells by RNAi-mediated Parc re-
duction. Parc-RNAi or control oligonucleotide
transfected SK-N-AS cells were treated with
0.25 M etoposide and analyzed for apo-
ptotic cells (sub-G1) according to DNA con-
tent (PI staining).
induces cytoplasmic sequestration of p53. Therefore, 1998; Stommel et al., 1999), several earlier studies pro-
posed that additional cytoplasmic factors may be re-we propose that Parc serves as an anchor protein that
tethers p53 in the cytoplasm and thereby regulates p53 quired for complete degradation of p53 in the cyto-
plasm––although more recent studies reported thatsubcellular localization.
Parc is a constitutive cytoplasmic protein that strongly degradation of p53 can also be carried out, to some
extent, by nuclear proteasomes (Xirodimas et al., 2001).interacts with the C-terminal domain of p53. Since this
domain harbors the three known NLS sequences of p53, Although Mdm2 is a potent ubiquitin ligase, it was re-
ported that Mdm2 more efficiently induces monoubiqui-it is conceivable that Parc blocks nuclear import of p53
by concealing its C-terminal NLS motifs. Interestingly, tination, but not polyubiquitination of p53 (Honda et al.,
1997; Lai et al., 2001). Since polyubiquitination is gener-overexpression of the p53 binding domain of Parc (resi-
dues 1–770) alone is not sufficient to induce cytoplasmic ally required for proteasome-mediated degradation
(Pickart, 2001), it is possible that there is another ubiqui-retention of p53 (Figure 6). Thus, it is likely that additional
Parc sequences such as the CCH domain facilitate cyto- tin ligase (E3) or multiubiquitin chain assembling enzyme
plasmic sequestration of p53, perhaps by linking the (E4) resides in the cytoplasm and contributes to the
Parc protein to stable cytoplasmic complexes/or struc- efficiency of p53 degradation.
tures. In any case, latent p53 is tightly associated with In several respects, the Parc protein is an appropriate
Parc in the cytoplasm of unstressed cells. However, in candidate for such a factor. Parc can tether p53 in the
response to DNA damage and other types of stress, p53 cytoplasm and like Parkin, it contains a signature ubiqui-
is rapidly stabilized and translocated into the nucleus tin ligase motif. Moreover, we have found that Parc has
while no significant effect on Parc subcellular localiza- an intrinsic ubiquitin ligase activity and can ubiquitinate
tion was observed (see Supplemental Figures S3 and itself very efficiently. However, Parc fails to induce direct
S4 online at http://www.cell.com/cgi/content/full/112/1/ ubiquitination of p53 to a significant degree in vivo or
29/DC1). As such, regulation of the Parc-p53 interaction in vitro. Moreover, ablation of endogenous Parc expres-
in response to stress is an extremely important issue that sion strongly induced p53 nuclear localization, but did
warrants further investigation. Since p53 is subjected to not significantly affect p53 protein levels. Thus, our
posttranslational modifications in stressed cells, it is study indicates that a primary function of Parc is to
possible that phosphorylation and/or acetylation of the control the subcellular localization of p53. We can not,
p53 protein may regulate its interaction with Parc. however, exclude the possibility that Parc is also in-
volved in the regulation of p53 ubiquitination in the pres-
ence of other cofactors. Very recently, the CHIP protein,Subcellular Localization and p53 Degradation
which contains a multiubiquitin chain assembling en-Based on the observations that p53 can be stabilized
by blocking the nuclear export (Freedman and Levine, zyme E4-like activity, was shown to interact functionally
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regular plasmids. RNAi transfections were performed using Oligo-and physically with the Ring-IBR-Ring domain of Parkin
fectamine Reagent (Invitrogen). 24 hr before transfection, about 1(Imai et al., 2002). Since Parc also contains the Ring-
million cells were plated on a 10 cm dish. Cells were transfectedIBR-Ring domain, it is possible that Parc may recruit
using manufacturer’s protocol (Invitrogen) for three times with 24–48
the CHIP-mediated E4 activity to induce polyubiquitina- hr intervals. After three consecutive transfections, cells were har-
tion of p53 for degradation. vested for the Western blot analysis, flow cytometry analysis, or
immunostaining.The relationship between Parc- and Mdm2-mediated
negative regulations on p53 needs to be further eluci-
DNA Damage Response and Immunofluorescent Stainingdated. Although both proteins are p53-associated ubi-
The assay for the DNA damage response was performed essentiallyquitin ligases, they apparently regulate p53 function
as described previously (Luo et al., 2001). Neuroblastoma cells werethrough different mechanisms. In fact, Mdm2 also plays
treated with 0.25 M etoposide for 8 hr, washed twice with PBS,
a critical role in promoting nuclear export of p53 in ad- and supplemented with fresh DMEM with 10% FBS. 36 hr after
dition to ubiquitination-mediated degradation of p53 treatment, cells were stained with PI and analyzed by flow cytometry
(Geyer et al., 2000; Boyd et al., 2000). Thus, it is most for apoptotic cells (subG1) according to DNA content. For immuno-
fluorescent staining, cells were grown on 8-well polylysine slideslikely that Parc and Mdm2 cooperatively regulate sub-
essentially as described previously (Guo et al., 2000). For the p53cellular localization and stability of p53 and more effec-
cytoplasmic sequestration assay, cells were transfected with 30 ng/tively keep p53 under control.
well CMV-p53 and 150 ng/well CMV-Parc. 24 hr posttransfection,
cells were fixed with 4% paraformaldehyde for 20 min on ice, rehy-Experimental Procedures
drated for 5 min in serum-free DMEM, and permeabilized with 0.2%
Triton X-100 (Fisher) for 10 min on ice. Cells were incubated inPlasmids and Antibodies
1% bovine serum albumin (BSA) (Sigma)/phosphate buffered saltTo construct Parc expresson constructs, the full-length Parc cDNA
solution (PBS) (Cellgro) for 30 min. Primary p53-specific monoclonalor deletion mutants were amplified by PCR from Marathon-Ready
(for endogenous p53 immunostaining) (DO-1, 1801, Santa Cruz) orHeLa cDNA (Clontech, BD) and subcloned into pcDNA3.1/V5-His-
polyclonal (for transfected p53 immunostaining) (FL-393, SantaTopo vector (Invitrogen). The Flag sequence was introduced to the
Cruz) antibodies or anti-Flag monoclonal antibody (for transfectedN terminus of Parc by PCR and subcloned into pcDNA3.1/V5-His-
Flag-Parc and Flag-Myc immunostaining) (Santa Cruz) were addedTopo vector (Invitrogen). To prepare the Parc antiserum, DNA se-
in 1% BSA/PBS for 45 min at room temperature. After washing withquences corresponding to the C-terminal 100 amino acids of Parc
1% BSA/PBS, Alexa-488 (or Alexa-568) conjugated anti-mouse (or(residues 2417–2517) were amplified by PCR (2417–2517) and sub-
anti-rabbit for polyclonal primary antibody) (Molecular Probes) anti-cloned into pGEX-2T (Luo et al., 2001). -Parc antiserum was raised
body was added and incubated for 30 min at room temperature.in rabbits against the purified GST-Parc (2417–2517) fusion protein
Finally, cells were counterstained with DAPI to visualize the nuclei(Covance) and further affinity-purified on the antigen column.
essentially as described before (Guo et al., 2000).
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